Teclistamab, an off-the-shelf (ready to use) subcutaneously administered therapy, induced deep and rapid responses in triple-class exposed patients with relapsed and refractory multiple myeloma1

August 24, 2022 08:13 AM Eastern Daylight Time

https://www.businesswire.com/news/home/20220822005274/en/Janssen-Marks-First-Approval-Worldwide-for-TECVAYLI▼-teclistamab-with-EC-Authorisation-of-First-in-Class-Bispecific-Antibody-for-the-Treatment-of-Patients-with-Multiple-Myeloma?utm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork